Market Overview

Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines

Share:
Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines

Morgan Stanley's Steve Beuchaw initiated Cepheid (NASDAQ: CPHD) at Equal-Weight with a $30.00 price target.

Beuchaw was especially worried about low margin expectations and future extensive spending. "CPHD is a share gainer in a healthy molecular diagnostics market, but we see limited upside to margin expectations, and new point-of-care/test menu initiatives will require incremental spending," said the analyst.

Positives

  • The company has grown revenue at 2.3x the 9 percent molecular diagnostics market rate and now holds 8–9 percent of the market.
  • Cepheid's GeneXpert "brings unmatched ease-of-use and a broad test menu" and has only penetrated 20 percent of the 5,000 smaller-sized hospitals in the United States.
  • GeneXpert's current Virology and Sexual health tests are in their early stages of market penetration and the analyst saw a "significant runway" for the drug in this sector.
  • Cepheid's solutions are a "solid fit for emerging markets testing as well, driving scale and a foothold in growth markets for the infectious disease MDx as governments/humanitarian organizations implement routine disease testing."
  • Cepheid now has "distribution partnerships driving access to the physician office market, an incremental 10,000 lab opportunity," according to the analyst.

Due to these opportunities and signs of strength, Beuchaw forecasts a 15 percent revenue '15–‘17E CAGR, in-line with CPHD's ~ 14–19 percent medium-term plan.

Related Link: Cepheid Reports WHO Prequalification Of Xpert HIV 1 Qualitative Test

Negatives

  • Healthcare-acquired infections (HAI) "were critical to growth over the last 5 years, but market penetration is materially above 50 percent in these categories and HAI growth has slowed to below 10 percent from ~15 percent in '10–'15."
  • Focus growth areas were more difficult to capture as international markets were more cost-sensitive. Additionally, this was due to Point-of-care markets being more competitive, and a lack of visibility in penetration.
  • U.S. structural change produces risk "to category growth as hospital labs transition from functioning as profit centers to cost centers" said the analyst.

Cepheid closed Wednesday trading at $28.66, up 2.07 percent on the day. However, shortly after the closing bell, the stock slipped 0.91 percent at time of writing.

Latest Ratings for CPHD

DateFirmActionFromTo
Sep 2016DowngradesOutperformNeutral
Sep 2016DowngradesBuyNeutral
Sep 2016MaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: GeneXpertMorgan StanleyAnalyst Color Biotech Price Target Initiation Analyst Ratings Trading Ideas General

 

Related Articles (CPHD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XELMaintains60.0
SOMaintains54.0
SREMaintains141.0
EXCMaintains56.0
ESMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Is A Synchrony Financial Sympathy Sell-Off Unwarranted?

Cynapsus Therapeutics Developing New Parkinson's Treatment That Won't Require Injection